COVID-19: Origin, Impact and Management (Part 2) E-Book
53,95 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
COVID-19 has spread like wildfire across the globe since the start of the SARS-CoV-2 outbreak, hampering quality of life at multiple levels and causing many deaths. Many aspects of the human experience have been affected, with a body of research being published on its effects on psychological and physical well being, loss of jobs, pay cuts, education, and unpaid caregiving. New findings on these aspects are still emerging as we learn more about the consequences of the pandemic.
This book is intended as a simple summary of recent findings about COVID-19 for academicians and students from science, humanities and commerce backgrounds to understand the pandemic from a microscopic view and how it has touched our lives at different levels.
A collection of topics is presented and explored through chapters dedicated to niche topics on COVID-19. Each chapter is authored by expert scientists, academicians and scholars from leading institutions in India.
The key features of this book set are:
- Interdisciplinary content, making it useful for readers from different academic streams
- A blend of basic and applied research in biology, medicine and social science
- A focus on findings from India
- Updated References for advanced readers
This collection of topics is invaluable for researchers and working professionals in industry and academia as well as general readers who want a broad, insightful perspective on COVID-19.
Das E-Book können Sie in Legimi-Apps oder einer beliebigen App lesen, die das folgende Format unterstützen:
Seitenzahl: 283
Veröffentlichungsjahr: 2009
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
FOREWORD I
I feel it a pleasure to write forward to the book titled “COVID-19: Origin, Impact and Management” edited by Dr. Alfred Lawrence and Dr. Tahmeena Khan. The SARS-CoV-2 or COVID-19 pandemic has jolted the entire world at different levels. It is not only the health sector that has been greatly impacted, but human life has suffered at multi-levels, be it psychological well-being, economic upheaval or discrimination in caregiving at home as faced by women. The education sector also saw reform as online mode took over. The situation is more severe and grim in developing countries and it is very important to find out the vulnerable groups, having access to lesser means of protection and prevention.
This innovative book is an interesting reading material as the assorted chapters cater to different aspects related to the pandemic. Several interesting case studies are conducting an in-depth analysis of the impact of the COVID-19 outbreak on different target groups. The management strategies and vaccine development have also been nicely explained. The interdisciplinary nature of the book makes it suitable for academicians and students belonging to science, humanities, and commerce background. The chapters are very well written and presented in an easy-to-understand manner.
FOREWORD II
It gives me immense pleasure to introduce the second part of the book COVID-19: Origin, Impact and Management ably edited by Dr. Tahmeena Khan and Dr. Alfred J. Lawrence. The book has covered many important aspects related to the COVID-19 mayhem which claimed millions of lives world over. The second part of the book has shed light on many important aspects like the effect of the pandemic on women and how they are adapting to the change in lifestyle. Not only this, but the book also includes chapters on computational drug discovery which may be useful to researchers working in medicinal chemistry. The chapters are composed and selected very ably and the authors have done a great job as all the chapters are well-written, informative and present facts in a beautiful manner.
I wish the editor great success and hope the readers would be benefitted from the enriching book.
PREFACE
The emergence of the COVID-19 pandemic was an unprecedented situation that impeded the physical and mental well-being of people globally. The expeditious discovery of vaccines and medication for decelerating the spread of SARS-CoV-2 catered to alleviating mortality rates. A comprehensive discussion on the pandemic and its impact on billions of lives has been done in part one of the two books. This part provides a meticulous overview of the COVID-19 pandemic. This book intends to collaboratively serve students, scientists and academicians from different academic areas such as science, humanities, economics; and even common masses. The collation of various heads in this book is based on contemporary needs and elaborately gives an insight into the pandemic, its impact on people’s lives, especially on women, the variations that it brought in the world, and the role of air quality in exacerbating the disease. Drug discovery and vaccination hesitancy-related challenges are also scrupulously described in this book. Authors from various eminent institutions have contributed to the book which makes it a valuable collection of information. Computational Drug Discovery against the pandemic, DFT studies and molecular docking, and drug repurposing for searching potential drug candidates are the highlights of the book. Special emphasis is laid on the impact of the COVID-19 pandemic on women. The book vouches to provide a deep insight into the outbreak, epidemiology, immunology and management of SARS-CoV-2 and will be valuable for evolutionary biologists, pharmaceutical scientists and doctors. In essence, the book will supply a plethora of relevant information for degree students, research scholars, academicians, scientists and anyone who finds an interest in gathering information about the disease.
List of Contributors
COVID-19 Pandemic: Outbreak, Epidemiology and Immunology
Uzma Afreen1,Ushna Afreen1,Daraksha Bano2,*Abstract
The SARS-CoV-2 virus-led COVID-19 pandemic jolted the whole world at different levels. Severe acute respiratory syndrome (SARS) caused death in severe cases leading to millions of mortalities. This chapter attempts to present an overview of the whole fiasco created by the spread of the virus along with the historical background, structural features and important proteins of the virus, modes of infection and transmission and different diagnostic means like viral and antibody tests. The authors have presented the latest statistical data on the number of cases and mortalities reported across the globe and also elaborated on the probable remedial interventions like the different antiviral, antimalarial drugs which are being explored for treatment and also explored the utility and applications of drug repurposing and computational strategies for drug development. The authors have also elaborated on the different vaccines developed to curb the disease and explained the development of COVID-19 vaccines for children. Overall the chapter has summarized key facts associated with COVID-19 in a nutshell and it may prove beneficial to the readers to understand the disease more clearly.
Introduction
The outbreak of the SARS-CoV-2 or COVID -19 virus has led to one of the worst pandemics in recent times. Coronaviruses (CoVs) have been recognized for over 50 years. The virologists derived the word “corona” from the sun comparing the characteristic projections on the surface of the virus with the solar corona. CoVs cause severe acute respiratory syndrome (SARS) which may lead to death in severe cases. These viruses chiefly infect human and non-human mammals and birds [1]. Coronaviruses are included in the subfamily Coronavirinae, in the
family Coronaviridae of the order Nidovirales [2]. Based on their phylogeny and genotype, this subfamily consists of four genera-Alphacoronavirus, Beta-coronavirus, Gammacoronavirus and Deltacoronavirus. The alphacoro-naviruses and betacoronaviruses infect only mammals, while the gammacoronaviruses and deltacoronaviruses chiefly infect birds, although some of them can also infect mammals [3]. Coronaviruses are single positive-sense RNA viruses which show greater mutation rates as compared to DNA viruses, owing to which they have better adaptation for survival. CoVs mainly affect birds and mammals. Before 2019, there were only six CoVs that were known to infect humans and caused respiratory diseases viz. HCoV-229E, HCoV-OC43, HCoV-NL63, HKU1, SARS-CoV and MERS-CoV. Among these, SARS-CoV and MERS-CoV have been reported to cause a severe respiratory syndrome in humans. MERS (Middle East respiratory syndrome) was first reported in Saudi Arabia in the year 2012. The COVID -19 virus, the causative agent for the coronavirus disease outbreak in 2019 emerged in Wuhan, Hubei Province, China. Wuhan, the epicentre of this virus, reported it first case in 2019. It was called Wuhan Novel Coronavirus (2019-nCoV). On the 31st of December 2019, the Chinese authorities alerted the World Health Organization (WHO) of a series of cases having pneumonia-like symptoms in the city of Wuhan. Shortly after the alert, it was recognized that the infections in humans likely originated from Huanan Seafood Market in Wuhan. After about two weeks, a team of Chinese scientists in collaboration with WHO announced that a new coronavirus (2019-nCoV), identified through genomic sequencing, was the causative agent of this pneumonia-like disease that originated in Wuhan [2]. On 9th January 2020, China declared that a novel coronavirus is the causative agent of this coronavirus disease outbreak in 2019 which is now known as COVID-19 [1]. This novel coronavirus named the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 or 2019-nCoV) radiated from Wuhan to other areas of China. It was found to possess high homology (~80%) to the SARS-CoV [4]. The virus that causes COVID-19 (SARS-COV-2) is identified to originate in bats from where it spread to humans through contamination of meat sold in Wuhan’s meat markets with wild animals’ wastes [1]. By January 7th 2020, a novel beta coronavirus, SARS-CoV-2, was identified. Mortality rates are higher among people over 60 years of age and with pre-existing medical problems such as hypertension, diabetes and cardiovascular disease [5]. COVID-19 represents a spectrum of clinical manifestations encompassing fever, dry cough, fatigue and other pneumonia-like symptoms. SARS-CoV-2 is highly contagious. The mode of transmission of the disease is droplet infection and direct contact. Although respiratory droplet and contact transmission are the main transmission routes for the spread of SARS-CoV-2, aerosol and faecal-oral transmissions might also be responsible for its transmission, but have not been confirmed yet [6, 7].
Historical Perspective
Origination of COVID-19 and Statistical Data
The ability of viruses to evolve quickly and unpredictably as they can mutate rapidly has posed great challenges to virologists. Their erratic behaviour has attracted researchers to understand their evolutionary modalities and develop strategies to subdue their activity. Many viruses have been causing various diseases in living organisms and have been, modifying their genome via mutation. This originates a need for continuous research on different viruses. Human viruses are distinguished based on their physical, chemical and biological properties into 26 distinct families. Coronaviridae is one of these families which includes highly infectious viruses which were earlier known to cause mild intestinal and respiratory infections in animals and humans. In the year 2002-2003, a very severe and fatal respiratory disease was encountered in Guangdong, China known as SARS which proved to be fatal. After a gap of nearly ten years another related and highly infectious strain, MERS originated in middle eastern countries where the first case was reported in the year 2012 in Jeddah, Saudi Arabia to be caused due to MERS-CoV (Middle East respiratory syndrome- coronavirus) [8]. Humans are highly susceptible to SARS-CoV and MERS-CoV (betacoronaviruses) which cause severe respiratory complications in humans. Other human coronaviruses cause mild upper respiratory tract infections with mild symptoms in adults these include HCoV-NL63, HCV-229E, HCV-OC43 and HKU1. Infants, elderly people and immunocompromised people (people with the impaired immune system) are susceptible to all the above types of human coronaviruses [3].
Later in December 2019 another fatal strain of Coronavirus came into existence in Wuhan City, China. It was named COVID-19 as it was first reported in the year 2019 [3]. A timeline of pandemics caused due to CoVs is represented in Fig. ( 1).
Fig. 1) Prominent Pandemics caused by CoVs.Morphological Features of SARS-CoV-2
An insight into the morphological details of SARS-CoV-2 played an instrumental role in elucidating its mechanism of action for causing infection. The general morphology of viruses includes the genome encapsulated within a protein coat. The size of virus particles is measured in micrometres (µm) or nanometers (nm) owing to their extremely small size. The virus particle of CoV measures nearly 120 nm or 0.12 µm [9].
A coronavirus is composed of two fundamental parts:
The genetic material: single-stranded RNAThe structural proteins.Genetic material of Coronavirus (SARS-CoV2):
The genetic material of a CoV is “enveloped positive-sense single-stranded RNA”. Having RNA as the genetic material makes it possible for CoVs to mutate at a faster rate. The RNA codes for the main structural proteins of the CoVs [2, 10].
The Structural Proteins:
The structural proteins are of four types:
1. Nucleocapsid Protein (N): binds to CoV genome to make nucleocapsid.
2. Spike Protein (S): binds to ACE2 receptors on the host cell, which causes its fusion to the host cell membrane thereby making its entry into the host cell.
3. Envelope Protein (E): participates in CoV assembly and budding.
4. Membrane Protein (M): crucial for the shape of the viral envelope. It works in coordination with other major coronaviral structural proteins [11]. Fig. (2) represents the basic structure of SARS-CoV-2.
Fig. 2) Basic structure of SARS-CoV- 2.Current Situation of COVID-19 all over the World
Soon after the onset of the COVID-19 pandemic, almost the entire globe was clutched by the SARS-CoV-2 which led to drastic life loss. Globally, as on 14th October 2022, there have been 620,878,405 confirmed cases of COVID-19, including 6,543,138 deaths, as reported by the WHO [12]. Table 1 shows the data on confirmed cases of COVID-19 in various regions worldwide.
Mode of Infection
The life cycle of the virus involves the following actions: attachment, penetration, biosynthesis, maturation and release. The attachment step involves the binding of the viruses to host receptors, thereafter the SARS-CoV-2 enters the host cells by endocytosis or membrane fusion. This particular step is called penetration. Once viral contents are released inside the host cells, viral RNA invades the nucleus and the process of replication sets in. Viral mRNA translates to synthesize viral proteins. This is a crucial step and is termed biosynthesis. New viral particles are produced in the next step called maturation followed by the release of the viruses. CoVs consist of four structural proteins; Spike (S), membrane (M), envelope (E) and nucleocapsid (N) [11]. Spike is composed of a transmembrane trimetric glycoprotein projecting from the viral surface, which determines the diversity of CoVs and host tropism. Spike comprises two functional subunits; S1 and S2 which are responsible for the binding to the host cell receptor and the fusion of the viral and cellular membranes respectively. Angiotensin-converting enzyme 2 (ACE2) has been identified as the functional receptor for SARS-CoVs. Structural and functional analysis of the SARS-CoV-2 indicated that the spike protein binds to ACE2. ACE2 expression is reported to be high in the lung, heart, ileum, kidney and bladder. In the lungs, ACE2 expression of the lung epithelial cells is very high. Subsequently, the spike protein undergoes protease cleavage once the SARS-CoV-2 binds to the host protein. After the cleavage at the S1/S2 cleavage site, both the S1 and S2 subunits stay persistently bound via a non-covalent interaction. The distal S1 subunit contributes to the stabilization of the membrane-anchored S2 subunit at the prefusion state. Subsequent cleavage at the S2 site is presumed to activate the spike protein for membrane fusion through irreversible conformational changes. The coronavirus spike is unusual among viruses because it can be cleaved by an array of proteases [13]. The main symptoms of COVID-19 include fever, cough, fatigue, and dyspnea hence playing a key role in the early detection of this disease and early diagnosis may help in preventing the transmission of the disease to other people. About 25% of patients suffer from the presence of sputum [14]. The source of origination and transmission were important to understand to develop preventive strategies to contain the infection.
Mode of Transmission
Wild animal hosts and infected patients are currently identified as the main sources of disease which is transmitted via respiratory droplets and direct contact [6]. Analogous to most respiratory viruses, SARS-CoV-2 transmits predominantly via respiratory droplets. It is the main route, although aerosols may also be a mode of transmission. The oral-faecal route may be another route of transmission of the virus but it has not been confirmed. The stool of a patient with COVID-19 pneumonia was detected with SARS-CoV-2 RNA. This envisages that sewage might have been a source of infection of SARS-CoV-2 in humans. Moreover, the virus has also been detected in the saliva of infected individuals. This is because the epithelial cells of the salivary gland duct have receptors or target cells for the virus. The urine of some COVID-19 sufferers had also been tested for SARS-CoV-2 viral RNA [15]. A major cause for the transmission of the SARS-CoV-2 RNA is the commonly touched surfaces such as door handles, switches, and cell phones in residential sites of COVID-19-affected patients. The objects used by people in quarantine who are either positive or suspected patients are a potential cause of transmission of viable SARS-CoV-2 and lead to the spread of the virus. The analysis of the samples obtained from frequently-touched surfaces such as telephones, chairs, door handles, trolleys, etc. has confirmed the presence of the virus on them [16]. Bats are speculated to be the carriers of several emerging viruses including CoVs. Bats that are infected with SARS-CoV-2 have not demonstrated clinical signs of disease showing that they act as the reservoirs or ancestral hosts for several CoVs [17]. Four stages of infection have been identified: the first stage is characterised by upper respiratory tract infection; the second stage involves the onset of dyspnoea and pneumonia; the third is characterized by the worsening clinical scenario dominated by a cytokine storm and the consequent hyperinflammatory state, and the fourth stage is either death or recovery of the patient [18]. Through the sequence homology comparison at the whole-genome level in samples obtained from seven patients shared 96.2% sequence identity was observed between SARS-CoV-2 with bat-coronavirus (bat-nCoV). The intermediate host has a critical role in the transmission of SARS-CoV-2. It has been concluded through a previously reported study that the intermediate host of SARS-CoV is masked palm civet. The host receptors mediate the entry of SARS-CoV-2 via binding to the receptor-binding domain (RBD) of the S protein [19]. Other animals harbouring the CoVs are cattle, horses, swine, dogs, cats, camels, rabbits, rodents, birds, snakes, hedgehogs, frogs, pangolins and many other wild animals. Thus, the CoVs infect man as well as domestic and wild animal species. As is clear from the preceding discussion, among the four genera in the Coronaviridae family, Alphacoronavirus and Betacoronavirus usually infect mammals and have probable bat origin, while Gammacoronavirus and Deltacoronavirus infect birds, fishes, and mammals and are assumed to have swine origin. The SARS-CoV-2 has bats as primary hosts and palm civet cats as intermediate hosts. However, many CoVs have been recovered from birds also. The pig-infecting CoVs predominantly include Porcine Coronavirus HKU15, Transmissible Gastroenteritis Virus (TGEV), Porcine Epidemic Diarrhoea Virus (PEDV), and Porcine Hemagglutinating Encephalomyelitis virus (PHEV) [20]. From the primary host or the natural reservoir of SARS-CoV-2 i.e., bats, the virus gets transmitted to the intermediate host. It then gets transmitted from the intermediate host to the human body. It is, therefore, necessary to devise measures to ensure that live-animal markets like the Huanan South China Seafood Market should be regulated by implementing strict disease-control mechanisms. Fig. (3) is a pictographic representation of the transmission route of the SARS-CoV-2 virus in the human population.
Fig. 3) A pictographic representation of the transmission of the SARS-CoV-2 virus in the human population.Measures to Contain COVID-19
Early diagnosis of any disease is crucial for its containment. Various diagnostic techniques are employed for the detection of SARS-CoV-2. These are broadly categorised as viral and antibody tests. These diagnostic techniques along with measures taken to contain the SARS-CoV-2 are meticulously discussed in the proceeding section.
Diagnosis
The diagnosis of SARS- The coV-2 virus responsible for COVID-19 is done with the help of several clinical tests as described below:
Viral testsThese tests find the current SARS-CoV-2 virus in samples collected for the nose or mouth of an individual. The two main types of viral tests are:
1. NAATs (Nucleic acid Amplification Tests)
One of the common NAATs is the RT-PCR (Reverse transcription-polymerase chain reaction) Test which is suitable for the detection of the genetic material of the virus. It can be employed for both symptomatic and asymptomatic individuals. Since virus genetic material stays in an individual for at least 90 days, it is advisable not to prefer this test if an individual is already tested positive in the last 90 days.
2. Antigen Test
It is a quick testing method but less reliable than RT-PCR (NAAT). It gives results in 15 minutes to 30 minutes. It can be used as a preliminary test but it is recommended to go for a NAAT for confirmation.
3. Self-Tests
These tests are antigen tests. It is done by an individual himself or herself using a self-test kit. there are various self-test kits available for purchase. It provides rapid results and is convenient option as it can be taken at any place. They test for current infection and are known as “home tests,” “at-home tests,” or “over-the-counter (OTC) tests”. Self-tests is not useful to detect antibodies.
Antibody or Serology TestThis test finds for antibody in the bloodstream that fights against the virus. This test is not preferred to diagnose current infection because it takes 1-3 weeks after the infection for the preparation of antibodies in the body [21].
Prevention
1. General Measures
COVID-19 spreads through respiratory droplets infection produced by infected individuals. When a healthy person comes in direct or indirect contact with infective droplets, that person also gets infected. Asymptomatic individuals can also spread the SARS-CoV-2 virus. Hence it becomes mandatory to take special preventive measures. Some of the standard operating procedures for the containment of COVID-19 are enlisted below:
Quarantine- WHO recommended a quarantine period of 14 days if a person comes in contact with a patient suffering from COVID-19. Self-quarantine is also advisable if a person observes COVID-19 symptoms in them. Those individuals who came in contact with any symptomatic person were also adviced to avoid meeting anyone for a period of atleast 14 days so as to prevent spread of infection. Moreover, public gatherings were not allowed as a measure to prevent progression of infection in the society. People who returned from international places were made to quarantine.Personal hygiene- It is very important to take care of personal hygiene to prevent the spread of any disease. Hence some of the important personal hygiene measures are recommended by WHO to prevent the spread of COVID-19. One should take care of some common hygiene practices like washing hands using soap for at least twenty seconds, avoiding touching your nose, mouth and face, use sanitisers to kill viruses on your hands.Social distancing- As recommended by WHO physical distance of at least one meter is mandatory to avoid spreading SARS-CoV-2 [22]. As a result of this the public transport system came to a halt. People were allowed to leave their homes in their personal vehicles only in case of emergency.2. Measures adopted by Governments all over the world
Complete lockdown during severe pandemic conditions.Demarcation of certain areas as containment zones.Closing schools and other educational institutions completely.Closing offices and introducing a” work from home” strategy.Strict restrictions on opening marketplaces and restaurants etc.Giving guidelines for the strict use of masks when moving out of the home.Spraying disinfectant in public places, hospitals and residential areas.Expanding COVID-19 testing capacity.Initiating and expanding vaccination drive [23].Probable Medicinal Intervention
Several treatments could be the first-line therapy for SARS-CoV-2 infection. These procedures have been tested on SARS-CoV-2-infected individuals. Although various vaccines having appreciable efficacy have been developed for COVID-19 but effective pharmacotherapy, including immunotherapy to avert the infection and for treatment, is yet to be established [24]. Several drugs have been used for treating COVID-19 patients. Some of these drugs and their efficacy and safety will be discussed in this section.
Antiviral Drugs
Several protease inhibitor drugs such as darunavir and atazanavir which are used for treating HIV (Human Immunodeficiency Virus) were found to inhibit the viral genome replication of SARS-CoV-2. This may be possible due to the inactivation of the proteases that are necessary to carry out replication [18, 25]. An antiviral drug, darunavir which is a nonpeptidyl HIV-1 protease inhibitor selectively inhibits Gag-Pol polyprotein cleavage resulting in immature non-infectious viral particles. Based on various in silico studies, darunavir has received a high score for binding with the SARS-CoV-2 protease. Thus, this drug seemed too useful for fighting the COVID-19 infection after a series of clinical testing [26
